OBJECTIVE: To determine the pharmacokinetic properties of dihydroartemisinin (DHA) following oral artesunate treatment in women with recrudescent multi-drug resistant falciparum malaria, in the second and third trimesters of pregnancy. METHODS: Serial plasma concentrations of artesunate and DHA were measured in 24 women after the final dose of a 3 day treatment with artesunate (4 mg kg(-1) day(-1)) and atovaquone (20 mg kg(-1) day(-1)) plus proguanil (8 mg kg(-1) day(-1)), daily. Conventional non-compartmental modelling and a population one-compartment pharmacokinetic model were applied to the data. RESULTS: Artesunate was very rapidly eliminated. For DHA the median [90% range] estimate of oral clearance (CI/F) was 4.0 [0.8-20.7] l hour(-1) kg(-1), total apparent volume of distribution (Vd/f) was 3.4 [0.9-60.7] l/kg, and terminal elimination half-life was 1.0 [0.6-2.4] h. CONCLUSION: The kinetics of DHA are modified by pregnancy. The plasma levels of the active antimalarial metabolite DHA are lower than reported previously in non-pregnant adults. Dose-optimisation studies in pregnant women are needed.
OBJECTIVE: To determine the pharmacokinetic properties of dihydroartemisinin (DHA) following oral artesunate treatment in women with recrudescent multi-drug resistant falciparum malaria, in the second and third trimesters of pregnancy. METHODS: Serial plasma concentrations of artesunate and DHA were measured in 24 women after the final dose of a 3 day treatment with artesunate (4 mg kg(-1) day(-1)) and atovaquone (20 mg kg(-1) day(-1)) plus proguanil (8 mg kg(-1) day(-1)), daily. Conventional non-compartmental modelling and a population one-compartment pharmacokinetic model were applied to the data. RESULTS:Artesunate was very rapidly eliminated. For DHA the median [90% range] estimate of oral clearance (CI/F) was 4.0 [0.8-20.7] l hour(-1) kg(-1), total apparent volume of distribution (Vd/f) was 3.4 [0.9-60.7] l/kg, and terminal elimination half-life was 1.0 [0.6-2.4] h. CONCLUSION: The kinetics of DHA are modified by pregnancy. The plasma levels of the active antimalarial metabolite DHA are lower than reported previously in non-pregnant adults. Dose-optimisation studies in pregnant women are needed.
Authors: F Nosten; M van Vugt; R Price; C Luxemburger; K L Thway; A Brockman; R McGready; F ter Kuile; S Looareesuwan; N J White Journal: Lancet Date: 2000-07-22 Impact factor: 79.321
Authors: P Teja-Isavadharm; G Watt; C Eamsila; K Jongsakul; Q Li; G Keeratithakul; N Sirisopana; L Luesutthiviboon; T G Brewer; D E Kyle Journal: Am J Trop Med Hyg Date: 2001-12 Impact factor: 2.345
Authors: P Newton; Y Suputtamongkol; P Teja-Isavadharm; S Pukrittayakamee; V Navaratnam; I Bates; N White Journal: Antimicrob Agents Chemother Date: 2000-04 Impact factor: 5.191
Authors: N X Khanh; P J de Vries; L D Ha; C J van Boxtel; R Koopmans; P A Kager Journal: Antimicrob Agents Chemother Date: 1999-03 Impact factor: 5.191
Authors: P E Rolan; A J Mercer; B C Weatherley; T Holdich; H Meire; R W Peck; G Ridout; J Posner Journal: Br J Clin Pharmacol Date: 1994-01 Impact factor: 4.335
Authors: F Nosten; C Luxemburger; F O ter Kuile; C Woodrow; J P Eh; T Chongsuphajaisiddhi; N J White Journal: J Infect Dis Date: 1994-10 Impact factor: 5.226
Authors: Joel Tarning; Rose McGready; Niklas Lindegardh; Elizabeth A Ashley; Mupawjay Pimanpanarak; Benjamas Kamanikom; Anna Annerberg; Nicholas P J Day; Kasia Stepniewska; Pratap Singhasivanon; Nicholas J White; François Nosten Journal: Antimicrob Agents Chemother Date: 2009-06-29 Impact factor: 5.191
Authors: Julie A Simpson; Kris M Jamsen; Ric N Price; Nicholas J White; Niklas Lindegardh; Joel Tarning; Stephen B Duffull Journal: Malar J Date: 2009-08-06 Impact factor: 2.979